Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy

J. N. Atkins; H. B. Muss; R. L. Capizzi; M. R. Cooper; J. Craig; J. M. Cruz; D. V. Jackson; B. Powell; F. Richards; C. L. Spurr

Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy

J. N. Atkins, H. B. Muss, R. L. Capizzi, M. R. Cooper, J. Craig, J. M. Cruz, D. V. Jackson, B. Powell, F. Richards, C. L. Spurr

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m²) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m². Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.

Original language	English (US)
Pages (from-to)	897-899
Number of pages	3
Journal	Cancer Treatment Reports
Volume	69
Issue number	7-8
State	Published - 1985

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{dc1ed664974f4468a23af43a17f2a634,

title = "Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy",

abstract = "Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m2) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m2. Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.",

author = "Atkins, {J. N.} and Muss, {H. B.} and Capizzi, {R. L.} and Cooper, {M. R.} and J. Craig and Cruz, {J. M.} and Jackson, {D. V.} and B. Powell and F. Richards and Spurr, {C. L.}",

year = "1985",

language = "English (US)",

volume = "69",

pages = "897--899",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "7-8",

}

TY - JOUR

T1 - Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy

AU - Atkins, J. N.

AU - Muss, H. B.

AU - Capizzi, R. L.

AU - Cooper, M. R.

AU - Craig, J.

AU - Cruz, J. M.

AU - Jackson, D. V.

AU - Powell, B.

AU - Richards, F.

AU - Spurr, C. L.

PY - 1985

Y1 - 1985

N2 - Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m2) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m2. Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.

AB - Nineteen patients with advanced malignancy participated in a phase I trial of high-dose cytarabine (ara-C) and cisplatin in combination. Dose and schedule were based on laboratory data indicating synergy for concurrent use of these drugs. Cisplatin (100 mg/m2) was administered during the 2nd and 3rd hours of a 3-hour ara-C infusion. The ara-C dose was escalated in subsequent patients following a starting dose of 1 g/m2. Two brief responses were noted. The study was terminated prematurely due to protracted (several weeks) nausea, occasional vomiting, and severe lassitude.

UR - http://www.scopus.com/inward/record.url?scp=0021972474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021972474&partnerID=8YFLogxK

M3 - Article

C2 - 4040427

AN - SCOPUS:0021972474

SN - 0361-5960

VL - 69

SP - 897

EP - 899

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 7-8

ER -

Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this